29-Dec-2025
Zymeworks Announces Participation in Upcoming Conferences
Globe Newswire (Tue, 2-Dec 4:05 PM ET)
Globe Newswire (Tue, 18-Nov 8:45 AM ET)
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
Globe Newswire (Tue, 18-Nov 1:01 AM ET)
Globe Newswire (Tue, 18-Nov 1:00 AM ET)
Key Catalysts Emerge in Oncology, Synthetic Biology, and M&A Activity as Markets Open
Globe Newswire (Mon, 17-Nov 10:48 AM ET)
Zymeworks’ Phase 3 Results Point to Ziihera as Potential New Standard of Care in HER2-Positive GEA
Market Chameleon (Mon, 17-Nov 5:31 AM ET)
Ziihera Achieves Landmark Phase 3 Results, Paving Way for New HER2-Positive GEA Treatment Standard
Market Chameleon (Mon, 17-Nov 2:06 AM ET)
Globe Newswire (Mon, 17-Nov 6:00 AM ET)
Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Globe Newswire (Thu, 6-Nov 4:05 PM ET)
Zymeworks Announces Participation in Upcoming Investor Conferences
Globe Newswire (Tue, 28-Oct 6:00 AM ET)
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Zymeworks trades on the NASDAQ stock market under the symbol ZYME.
As of December 29, 2025, ZYME stock price declined to $26.74 with 368,164 million shares trading.
ZYME has a beta of 1.06, meaning it tends to be more sensitive to market movements. ZYME has a correlation of 0.11 to the broad based SPY ETF.
ZYME has a market cap of $2.02 billion. This is considered a Mid Cap stock.
Last quarter Zymeworks reported $28 million in Revenue and -$.26 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.05.
In the last 3 years, ZYME traded as high as $28.49 and as low as $6.02.
The top ETF exchange traded funds that ZYME belongs to (by Net Assets): VTI, IWM, IBB, IWO, VTWO.
ZYME has outperformed the market in the last year with a price return of +84.4% while the SPY ETF gained +16.8%. ZYME has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +55.2% and +3.0%, respectively, while the SPY returned +3.9% and +1.3%, respectively.
ZYME support price is $26.15 and resistance is $27.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZYME shares will trade within this expected range on the day.